From induced pluripotent stem cell (iPSC) to universal immune cells: literature review of advances in a new generation of tumor therapies

被引：0

作者：

Zhang, Jing ^{[1
,2
]}

Jia, Zixuan ^{[2
]}

Pan, Huixin ^{[2
]}

Ma, Wen ^{[2
]}

Liu, Youhan ^{[2
]}

Tian, Xuewen ^{[2
]}

Han, Yang ^{[1
]}

Wang, Qinglu ^{[2
]}

Zhou, Caixia ^{[2
]}

机构：

[1] Qilu Med Univ, Coll Pharm, 2018 Jiangmeng Rd, Zibo 255000, Peoples R China

[2] Shandong Sport Univ, Grad Sch Educ, 10600 Century Ave, Jinan 250102, Peoples R China

来源：

TRANSLATIONAL CANCER RESEARCH | 2024年 / 14卷 / 04期

关键词：

Induced pluripotent stem cell technology (iPSC technology); chimeric antigen receptor T cells (CAR-T); tumor therapies; chimeric antigen receptor-natural killer (CAR-NK); NATURAL-KILLER-CELLS; NK CELLS; CAR-T; MEMORY; ACTIVATION;

D O I：

10.21037/tcr-24-1087

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background and Objective: Tumor therapy is still a tough clinical challenge, and cancer immunotherapy has drawn increasing attention. T cells and natural killer (NK) cells play crucial roles in the immune response. Induced pluripotent stem cell (iPSC) technology opens up a new way to produce functionally improved universal iPSC-derived chimeric antigen receptor (CAR) T (CAR-iT) and iPSC-derived CAR-NK (CAR-iNK) cells. This study aims to comprehensively review the generation and clinical applications of iPSC-derived universal CAR-iT and CAR-iNK cells to explore their potential and future directions in cancer immunotherapy. Methods: We searched EBSCO, PubMed, and Web of Science databases for relevant literature from 1975 to 2024 on the transformation of iPSCs into universal immune cells. Key Content and Findings: iPSC technology enables the generation of enhanced CAR-iNK cells. Genetic modifications can boost the antitumor activity of iPSC-derived immune cells. CAR-iT cells have cytotoxicity issues. In contrast, CAR-iNK cells have advantages as they can be sourced from different origins and enhanced via genetic engineering. Conclusions: This review outlines iPSC technology's application in oncology, iNK cells' properties, and the pros and cons of CAR cells in cancer treatment. It also focuses on the current clinical status and modification strategies of CAR-iT and CAR-iNK therapies, facilitating the development of future effective off-the-shelf blood cell therapies.

引用

页码：2495 / 2507

页数：13

共 96 条

[41] T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial [J].

Lee, Daniel W. ;

Kochenderfer, James N. ;

Stetler-Stevenson, Maryalice ;

Cui, Yongzhi K. ;

Delbrook, Cindy ;

Feldman, Steven A. ;

Fry, Terry J. ;

Orentas, Rimas ;

Sabatino, Marianna ;

Shah, Nirali N. ;

Steinberg, Seth M. ;

Stroncek, Dave ;

Tschemia, Nick ;

Yuan, Constance ;

Zhang, Hua ;

Zhang, Ling ;

Rosenberg, Steven A. ;

Wayne, Alan S. ;

Mackall, Crystal L. .

LANCET, 2015, 385 (9967) :517-528

[42] Efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy in the treatment of relapsed and refractory multiple myeloma: a systematic-review and meta-analysis of clinical trials [J].

Li, Jingjing ;

Tang, Yuanyan ;

Huang, Zhiping .

TRANSLATIONAL CANCER RESEARCH, 2022, 11 (03) :569-579

[43] Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity [J].

Li, Ye ;

Hermanson, David L. ;

Moriarity, Branden S. ;

Kaufman, Dan S. .

CELL STEM CELL, 2018, 23 (02) :181-+

[44] IPSC-derived CAR-NK cells for cancer immunotherapy [J].

Lin, Xiaotong ;

Sun, Yao ;

Dong, Xin ;

Liu, Zishen ;

Sugimura, Ryohichi ;

Xie, Guozhu .

BIOMEDICINE & PHARMACOTHERAPY, 2023, 165

[45] Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors [J].

Liu, Enli ;

Marin, David ;

Banerjee, Pinaki ;

Macapinlac, Homer A. ;

Thompson, Philip ;

Basar, Rafet ;

Kerbauy, Lucila Nassif ;

Overman, Bethany ;

Thall, Peter ;

Kaplan, Mecit ;

Nandivada, Vandana ;

Kaur, Indresh ;

Cortes, Ana Nunez ;

Cao, Kai ;

Daher, May ;

Hosing, Chitra ;

Cohen, Evan N. ;

Kebriaei, Partow ;

Mehta, Rohtesh ;

Neelapu, Sattva ;

Nieto, Yago ;

Wang, Michael ;

Wierda, William ;

Keating, Michael ;

Champlin, Richard ;

Shpall, Elizabeth J. ;

Rezvani, Katayoun .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (06) :545-553

[46] Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice [J].

Liu, Xiaojun ;

Jiang, Shuguang ;

Fang, Chongyun ;

Yang, Shiyu ;

Olalere, Devvora ;

Pequignot, Edward C. ;

Cogdill, Alexandria P. ;

Li, Na ;

Ramones, Melissa ;

Granda, Brian ;

Zhou, Li ;

Loew, Andreas ;

Young, Regina M. ;

June, Carl H. ;

Zhao, Yangbing .

CANCER RESEARCH, 2015, 75 (17) :3596-3607

[47] Metabolic reprogramming in the tumor microenvironment: unleashing T cell stemness for enhanced cancer immunotherapy [J].

Liu, Youhan ;

Wang, Tao ;

Ma, Wen ;

Jia, Zixuan ;

Wang, Qinglu ;

Zhang, Maoling ;

Luo, Ying ;

Sun, Hongmei .

FRONTIERS IN PHARMACOLOGY, 2023, 14

[48] The tumourigenicity of iPS cells and their differentiated derivates [J].

Liu, Zhiqiang ;

Tang, Yu ;

Lu, Shuanghong ;

Zhou, Jin ;

Du, Zhiyan ;

Duan, Cuimi ;

Li, Zhiyan ;

Wang, Changyong .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2013, 17 (06) :782-791

[49] IN SEARCH OF THE MISSING SELF - MHC MOLECULES AND NK CELL RECOGNITION [J].

LJUNGGREN, HG ;

KARRE, K .

IMMUNOLOGY TODAY, 1990, 11 (07) :237-244

[50] CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances [J].

Maalej, Karama Makni ;

Merhi, Maysaloun ;

Inchakalody, Varghese P. ;

Mestiri, Sarra ;

Alam, Majid ;

Maccalli, Cristina ;

Cherif, Honar ;

Uddin, Shahab ;

Steinhoff, Martin ;

Marincola, Francesco M. ;

Dermime, Said .

MOLECULAR CANCER, 2023, 22 (01)

← 1 2 3 4 5 6 7 8 9 10 →